Congenital heart defects, especially valvular diseases, present major pediatric care challenges, often requiring valve replacements as children grow. Traditional treatments frequently fall short, highlighting the need for innovative approaches. This study investigates tissue-engineered, elastin-rich, valves that can adapt and grow with patients. By embedding allogeneic valves with extracellular matrix (ECM) components, the goal is to naturally attract native heart valve cells and support somatic growth. Elastin-rich valves are particularly focused on their ability to attract cells and stimulate tissue expansion. This research evaluates these bioengineered valves through experiments involving immune and native heart valve cell co-cultures, examining cytokine activation and ECM production, including muscle cell integration, and elastin, collagen, and mucin generation. Findings show increased cytokine and ECM component levels, suggesting that these tissue-engineered valves could be a long-lasting, growth-compatible treatment for pediatric patients with valvular heart diseases, representing a significant advancement in congenital heart defect care.